KALV (KalVista Pharmaceuticals) 6-1 Month Momentum % : 6.33% (As of Apr. 09, 2025)

View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-09), KalVista Pharmaceuticals's 6-1 Month Momentum % is 6.33%.

The industry rank for KalVista Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

KALV's 6-1 Month Momentum % is ranked better than
74.34% of 1473 companies
in the Biotechnology industry
Industry Median: -14.29 vs KALV: 6.33

Competitive Comparison of KalVista Pharmaceuticals's 6-1 Month Momentum %

For the Biotechnology subindustry, KalVista Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's 6-1 Month Momentum % falls into.

Save Embed

;

Save Embed

;

KalVista Pharmaceuticals (NAS:KALV) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals (NAS:KALV) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

KalVista Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

Executives

Benjamin L Palleiko	officer: CFO and Secretary	C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Paul K. Audhya	officer: Chief Medical Officer	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Christopher Yea	officer: Chief Development Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Edward P. Feener	officer: Chief Scientific Officer	ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett	director, officer: President and CEO	BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Albert Cha	director	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor	director	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith	officer: Senior VP, Development	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel	officer: Senior Vice President Medical	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart	director	99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira	director	C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p.	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108